tracon
pharmaceuticals
highlights
updated
envafolimab
clinical
results
dmmr
colorectal
cancer
san
diego
globe
newswire
tracon
pharmaceuticals
nasdaq
tcon
clinical
stage
biopharmaceutical
company
focused
development
commercialization
novel
targeted
cancer
therapeutics
utilizing
cost
efficient
product
development
platform
partner
companies
develop
commercialize
innovative
products
today
highlighted
updated
clinical
data
pivotal
trial
envafolimab
dmmr
cancer
patients
recently
presented
company
corporate
partners
medicines
alphamab
oncology
presentation
highlighting
updated
clinical
results
chinese
society
clinical
oncology
csco
virtual
scientific
program
entitled
subcutaneous
injection
antibody
envafolimab
advanced
tumors
deficiency
single
agent
envafolimab
shown
confirmed
objective
response
rate
orr
central
radiographic
review
patients
dmmr
colorectal
cancer
crc
failed
fluoropyrimidine
oxaliplatin
irinotecan
least
two
tumor
assessments
duration
response
dor
greater
equal
months
patients
overall
survival
os
greater
equal
months
patients
orr
overall
population
dor
greater
equal
months
patients
os
greater
equal
months
patients
envafolimab
demonstrated
good
tolerability
safety
continued
reactions
earlier
data
trial
presented
medicines
alphamab
oncology
asco
presentation
entitled
envafolimab
advanced
tumors
deficiency
time
single
agent
envafolimab
shown
confirmed
orr
central
radiographic
review
patients
dmmr
crc
failed
fluoropyrimidine
oxaliplatin
irinotecan
least
two
tumor
assessments
trial
enrolled
patients
crc
gc
dmmr
advanced
solid
tumors
clinical
sites
china
open
label
format
efficacy
endpoints
including
primary
endpoint
confirmed
orr
determined
independent
central
review
dmmr
status
assessed
centrally
crc
gc
locally
tumors
confirmed
orr
dmmr
colorectal
cancer
patients
treated
envafolimab
failed
fluoropyrimidine
oxaliplatin
irinotecan
reported
csco
similar
confirmed
orr
reported
opdivo
package
insert
dmmr
colorectal
cancer
patients
failed
fluoropyrimidine
oxaliplatin
irinotecan
confirmed
orr
reported
keytruda
dmmr
crc
patients
failed
fluoropyrimidine
oxaliplatin
irinotecan
seen
cohort
pivotal
trial
csco
data
provide
clinical
evidence
envafolimab
activity
similar
opdivo
keytruda
dmmr
cancer
also
impressive
durability
response
months
said
james
freddo
tracon
chief
medical
officer
given
orr
reported
pivotal
study
votrient
approved
therapy
refractory
ups
mfs
demonstrated
efficacy
immune
checkpoint
inhibitors
populations
believe
clinical
results
envasarc
pivotal
trial
positive
could
position
envafolimab
transformative
new
standard
care
sarcoma
patients
moreover
elimination
associated
reactions
observed
date
convenience
provided
envafolimab
subcutaneously
administered
inhibitor
currently
studied
registrational
trials
could
provide
significant
benefits
clinicians
envasarc
key
elements
planned
envasarc
pivotal
trial
include
randomized
parallel
cohort
study
approximately
top
cancer
centers
united
states
eligible
patients
undifferentiated
pleomorphic
sarcoma
ups
myxofibrosarcoma
mfs
received
one
two
prior
cancer
therapies
prior
immune
checkpoint
inhibitor
therapy
planned
total
enrollment
patients
patients
enrolled
cohort
treatment
single
agent
envafolimab
patients
enrolled
cohort
b
treatment
envafolimab
yervoy
primary
endpoint
confirmed
orr
duration
response
key
secondary
endpoint
format
blinded
independent
central
review
efficacy
endpoint
data
envafolimab
envafolimab
novel
antibody
first
subcutaneously
administered
l
inhibitor
studied
registrational
trials
envafolimab
currently
dosing
phase
registration
trial
single
agent
dmmr
advanced
solid
tumor
patients
phase
registration
trial
combination
gemcitabine
oxaliplatin
advanced
biliary
tract
cancer
patients
china
medicines
alphamab
oncology
tracon
corporate
partners
program
plan
submit
bla
nmpa
china
envafolimab
based
orr
dmmr
advanced
solid
tumor
patients
confirmed
orr
dmmr
colorectal
cancer
patients
treated
envafolimab
failed
fluoropyrimidine
oxaliplatin
irinotecan
reported
csco
similar
confirmed
orr
reported
opdivo
package
insert
dmmr
colorectal
cancer
patients
failed
fluoropyrimidine
oxaliplatin
irinotecan
confirmed
orr
reported
keytruda
dmmr
crc
patients
failed
fluoropyrimidine
oxaliplatin
irinotecan
cohort
tracon
tracon
develops
targeted
therapies
cancer
utilizing
capital
efficient
cro
independent
product
development
platform
company
pipeline
includes
envafolimab
subcutaneous
antibody
developed
treatment
sarcoma
goal
initiating
registrational
trial
fourth
quarter
phase
ready
small
molecule
drug
candidate
treatment
prostate
cancer
phase
small
molecule
drug
candidate
development
treatment
lung
cancer
phase
antibody
development
treatment
advanced
solid
tumors
tracon
actively
seeking
additional
corporate
partnerships
whereby
leads
regulatory
clinical
development
shares
cost
risk
clinical
development
leads
commercialization
partnerships
tracon
believes
serve
solution
companies
without
clinical
commercial
capabilities
learn
tracon
product
pipeline
visit
tracon
website
statements
statements
made
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
statements
include
limited
statements
regarding
tracon
partners
plans
develop
product
candidates
expectations
regarding
timing
scope
clinical
trials
availability
clinical
data
expected
development
regulatory
milestones
timing
thereof
tracon
business
development
strategy
goals
enter
additional
collaborations
risks
could
cause
actual
results
differ
expressed
statements
include
risks
associated
clinical
development
whether
tracon
others
able
complete
initiate
clinical
trials
tracon
expected
timelines
including
due
risks
associated
pandemic
pandemics
fact
future
preclinical
studies
clinical
trials
may
successful
otherwise
consistent
results
prior
studies
fact
interim
data
clinical
trials
may
consistent
future
final
data
trials
fact
tracon
limited
control
whether
third
party
collaborators
complete
trials
initiate
additional
trials
seek
regulatory
approval
tracon
product
candidates
fact
tracon
collaboration
agreements
subject
early
termination
whether
tracon
able
enter
additional
collaboration
agreements
favorable
terms
potential
changes
regulatory
requirements
united
states
foreign
countries
tracon
reliance
third
parties
development
product
candidates
including
conduct
clinical
trials
manufacture
product
candidates
whether
tracon
able
obtain
additional
financing
risks
described
tracon
filings
securities
exchange
commission
heading
risk
factors
statements
contained
press
release
speak
date
made
based
management
assumptions
estimates
date
tracon
undertakes
obligation
update
statements
reflect
events
occur
circumstances
exist
date
made
company
contact
investor
contact
mark
wiggins
brian
ritchie
chief
business
officer
lifesci
advisors
llc
mwiggins
britchie
